Med LifeLTS:0RO5 75 EBIT per Share is lei0.16 as of Mar. 2026. GuruFocus rates LTS:0RO5 with a GF Score™ of 75/100 and a GF Value™ of lei1.40 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 528 Healthcare Providers & Services companies, Med Life ranks worse than 75.38% on this metric.
Med Life's EBIT per Share for the
three
months ended in Mar. 2026 was lei0.08.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was lei0.16.
During the past 12 months, the average EBIT per Share Growth Rate of Med Life was 12.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -5.10% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 11.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Med Life's EBIT per Share or its related term are showing as below:
LTS:0RO5'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -7.6 Med: 21.2 Max: 66.6
Current: -5.1
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Med Life was 66.60% per year. The lowest was -7.60% per year. And the median was 21.20% per year.
LTS:0RO5's 3-Year EBIT Growth Rate is ranked worse than 75.38% of 528
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs LTS:0RO5: -5.10
Med Life's EBIT for the
three
months ended in Mar. 2026 was lei43 Mil.
Med Life (LTS:0RO5) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Med Life EBIT per Share Related Terms
Med Life EBIT per Share Historical Data
* Premium members only.
The historical data trend for Med Life's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei0.16
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a EBIT per Share of lei0.16 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Med Life and its competitors. According to the industry distribution chart, Med Life ranks #398 out of 528 companies in the Healthcare Providers & Services industry, placing it in the top 75.4%.
Is Med Life's EBIT per Share too high?
Med Life's current EBIT per Share is lei0.16. Based on the distribution chart, Med Life ranks #398 out of 528 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's EBIT per Share compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #398 out of 528 companies for EBIT per Share. This places Med Life in the lower half of its industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 528 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current EBIT per Share is lei0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.40, compared to a current price of lei11.38 — trading 712.5% above its estimated fair value. The current EBIT per Share is lei0.16. Med Life's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current EBIT per Share is lei0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.38 is trading 712.5% above its estimated GF Value™ of lei1.40.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
EBIT per Share: lei0.16
GF Value™: lei1.40 vs. price of lei11.38 (712.5% above fair value)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
75GF Score
Get the complete analysis for LTS:0RO5
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
